JaLCDOI 10.18926/AMO/57716
FullText URL 73_6_517.pdf
Author Hosogi, Mika| Shiode, Yusuke| Morizane, Yuki| Kimura, Shuhei| Hosokawa, Mio| Doi, Shinichiro| Toshima, Shinji| Takahashi, Kosuke| Fujiwara, Atsushi| Shiraga, Fumio|
Abstract We investigated the effectiveness of a treat-and-extend regimen (TAE) of intravitreal ranibizumab injections for macular edema (ME) due to branch retinal vein occlusion (BRVO). We retrospectively examined 2-year results of 32 eyes of 32 patients who underwent TAE to treat ME due to BRVO. The patients whose treatment interval extended to ≥ 12 weeks were switched to a pro re nata regimen (PRN). For the patients whose treatment interval was <12 weeks, TAE was continued. At 2 years, 10 eyes had required no additional injections after the initial treatment period [recurrence(−) group], whereas the other 22 eyes required additional treatment [recurrence(+) group]. Among the recurrence(+) patients, 11 eyes (34.4% of total) were eventually switched from TAE to PRN; the other 11 eyes (34.4%) continued TAE for 2 years. Visual acuity and central retinal thickness were significantly improved in both the recurrence(+) and (−) groups, and there was no significant betweengroup difference in visual acuity at 2 years. Univariate analyses revealed significant differences in visual acuity (p=0.004), age (p=0.014), and vessel occlusion site (p=0.018) between these groups. Our results suggest that TAE may be effective for BRVO patients with lower visual acuity, older age, and occlusion of a major vein.
Keywords branch retinal vein occlusion macular edema anti-vascular endothelial growth factor ranibizumab treat-and-extend regimen
Amo Type Original Article
Published Date 2019-12
Publication Title Acta Medica Okayama
Volume volume73
Issue issue6
Publisher Okayama University Medical School
Start Page 517
End Page 522
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2019 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 31871334
Web of Sience KeyUT 000503431400007
JaLCDOI 10.18926/AMO/56175
FullText URL 72_4_379.pdf
Author Morizane-Hosokawa, Mio| Morizane, Yuki| Kimura, Shuhei| Shiode, Yusuke| Hirano, Masayuki| Doi, Shinichiro| Toshima, Shinji| Hosogi, Mika| Fujiwara, Atsushi| Shiraga, Fumio|
Abstract We conducted intravitreal aflibercept injections (IVAs) for 37 Japanese patients (28 males, 9 females, mean age 73.4 years) with polypoidal choroidal vasculopathy (PCV), with a treat-and-extend regimen (TER). We evaluated the impact of polyp regression after a loading dose (2-mg IVA 1×/month for 3 months) on the patients' 2-year treatment outcomes. Thirty-seven eyes were treated with IVA by a TER for 2 years. We divided the patients into 2 groups based on their polyp status after the loading dose: polyp regression (PR+) (n=19) and no polyp regression (PR−) (n=18). We compared the groups’ best-corrected visual acuity (BCVA), central retinal thickness (CRT), recurrence rate, total number of injections, and final treatment interval. Both the BCVA and CRT were significantly improved by the treatment in both groups, with no between-group difference in the amount of change (p=0.769). In the polyp regression (+) group, recurrence was significantly less common (p=0.03), the mean total number of injections was significantly lower (p=0.013), and the mean treatment interval was significantly longer (0.042). Regarding the 2-year outcomes for PCV, the eyes with post-loading-dose polyp regression demonstrated less frequent recurrence and required fewer numbers of injections compared to the eyes without polyp regression.
Keywords polypoidal choroidal vasculopathy aflibercept treat-and-extend regimen polyp regression
Amo Type Original Article
Published Date 2018-08
Publication Title Acta Medica Okayama
Volume volume72
Issue issue4
Publisher Okayama University Medical School
Start Page 379
End Page 385
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2018 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 30140086
JaLCDOI 10.18926/AMO/55661
FullText URL 72_1_39.pdf
Author Hosogi, Mika| Morizane, Yuki| Shiode, Yusuke| Doi, Shinichiro| Kumase, Fumiaki| Kimura, Shuhei| Hosokawa, Mio| Hirano, Masayuki| Toshima, Shinji| Takahashi, Kosuke| Fujiwara, Atsushi| Shiraga, Fumio|
Abstract To investigate the effectiveness of a treat-and-extend regimen (TAE) of intravitreal ranibizumab injections (IVR) for macular edema (ME) due to branch retinal vein occlusion (BRVO). We retrospectively examined 35 eyes of 35 patients with ME due to BRVO who underwent TAE for 1 year. Patients whose treatment interval extended to 12 weeks were switched to a pro re nata regimen (PRN; TAE to PRN group), while TAE was continued for patients whose treatment interval was less than 12 weeks (continued TAE group). Changes in best-corrected visual acuity (BCVA), central retinal thickness (CRT), and predictive factors for inclusion in the TAE to PRN group were analyzed. BCVA and CRT both improved significantly at 1 year compared with baseline (p<0.001). Sixteen eyes (45.7%) were included in the TAE to PRN group, while 19 eyes (54.3%) were included in the continued TAE group. BCVA in the TAE to PRN group was significantly better than that in the continued TAE group at 1 year (p=0.047). BCVA at baseline and macular BRVO were significant predictive factors for inclusion in the TAE to PRN group. TAE was effective for improving BCVA and CRT. The TAE to PRN group showed significantly better prognosis.
Keywords branch retinal vein occlusion macular edema anti-vascular endothelial growth factor ranibizumab treat-and-extend regimen
Amo Type Original Article
Published Date 2018-02
Publication Title Acta Medica Okayama
Volume volume72
Issue issue1
Publisher Okayama University Medical School
Start Page 39
End Page 45
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2018 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 29463937
Web of Science KeyUT 000426542800006
NAID 120006398861